This is a proof (draft) Hansard, not the final version.
The Parliament had not yet published the final text for this day when we fetched it, so the wording, who said what and the results of divisions may differ from the final text.
Senate debates Bills
Private Health Insurance (National Joint Replacement Register Levy) Amendment Bill 2026; Second Reading
Carol Brown Tasmania, Australian Labor Party
6:46 pm
I rise to support the Private Health Insurance (National Joint Replacement Register Levy) Amendment Bill 2026. It changes how medical device companies share the cost of running the national joint replacement registry. It does not change what the registry does, and it does not impose a new charge on patients.
For someone living with a painful joint, a replacement can mean being able to walk more comfortably, return to work or get through the ordinary tasks of the day with less difficulty. Those are the things a person wants to be able to talk about with their surgeon. What they may not see is the work that goes on after the operation, to understand how joint replacements are performing and what can be learnt for the next patient.
The Australian Orthopaedic Association established the registry in 1999 and still runs it. It collects information from hospitals around the country on joint replacements and their outcomes. It covers more than hips and knees, and, because it brings records together nationally and over time, it can tell clinicians more than they can learn from the results of a single hospital.
If a particular implant is associated with more repeat operations than others, that is something clinicians need to know. A repeat operation to replace or alter part or all of an earlier joint replacement is known is known as revision surgery. For the person having it, it can mean another period of recovery and another interruption to work or daily life. It also means further treatment and use of hospital resources.
Better evidence about which devices and surgical approaches perform well can help a surgeon and patient weigh their options. It cannot guarantee the outcome of an operation, but it gives them better information to make that decision. That is why our national registry matters in Tasmania. A patient having surgery in our state should benefit from what clinicians and hospitals elsewhere in Australia have learnt. What we learn in Tasmania can help inform care elsewhere, too. I acknowledge the Australian Orthopaedic Association and the hospital staff and clinicians who make it possible to build and maintain that record.
The Commonwealth funds parts of the registry's administration under a grant agreement and recovers those costs through a levy on sponsors of relevant devices. In this context, a sponsor is a business, such as a manufacturer or distributor, responsible for a device on the Prescribed List of Medical Devices and Human Tissue Products. The cost recovery arrangement has been in place since 2009. The question before the Senate is not whether to establish a new funding arrangement; it is whether the current levy shares the cost fairly. At present, the levy for the same joint replacement cannot exceed $5,000 for a sponsor in any financial year. That figure is an annual limit in the levy calculation. It is not a $5,000 charge on an operation or on an individual implant. The calculation takes into account how often the provision of a device is recorded, the device's benefit amount and the funding needed for the registry. When a device reaches the cap, its contribution stops rising, and the costs of running the registry still have to be met. That affects how much of the total falls to other sponsors.
The government's cost recovery review found that this left smaller and medium-sized companies bearing a disproportionate share. The Parliamentary Library Bill's Digest records that 40 sponsors were liable to pay the levy in 202-26. Twenty-two of them had devices subject to the cap, so this is not a provision that has been sitting on the books without much effect; it has made a difference to how the costs are divided. This bill delivers the 2025-26 budget decision to remove the $5,000 cap. That allows the levy to reflect more closely the volume of devices a company supplies, rather than limiting the contribution for a device that is supplied in large numbers and leaving other sponsors to make up the difference.
The explanatory memorandum records that the bill has no financial impact on the Commonwealth, that it is a separate question from how much each company will contribute. Some contributions can change precisely because the bill is changing how the costs are shared.
There are two dates worth distinguishing. The legislation would commence on the 28th day after royal assent, allowing time for the levy rules to be updated. The change would apply to the levy for the financial year beginning 1 July 2027 and for later financial years. Commencement and the first levy year affected are not the same thing.
The consultation on the cost recovery statement raised a wider issue about who benefits from the registry and who should contribute to its costs. It is reasonable to ask those questions, but the Senate can recognise the wider discussion and still make a decision on the Pacific inequity before us. We do not need to leave the cap in place while every question about funding is considered, nor should we ask the bill to do more than it can. It does not add operating lists or change how long someone waits for elective surgery. Those are separate matters. This bill makes the funding arrangements fairer for an existing service that helps clinicians understand how joint replacements are performing and use that knowledge in caring for patients.
Patients should be able to have confidence that the health system continues to learn from their surgery long after they leave hospital. The registry gives clinicians a way to do that. It is reasonable to maintain that work through an existing levy and it is reasonable to ask the companies whose devices are recorded to share the costs more fairly. So as I've said, the Private Health Insurance (National Joint Replacement Register Levy) Amendment Bill 2026 that we're discussing here is a decision to amend the act of 2029 to remove the $5,000 cap per medical device, per financial year. By limiting or eliminating the cap, the amendment ensures the levy, which is important, is allocated in proportion to the actual volume of devices supplied by medical device companies. Again, I say to the Senate that removing the cap will ensure the levy is actual volume of devices supplied, creating a fairer and more equitable distribution of the levy. I commend the bill to the Senate.
No comments